Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
Demand normalisation post the second wave contributed to the steady growth
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
Anti-malaria API facility will be operational in 15-18 months
Income declines marginally
Subscribe To Our Newsletter & Stay Updated
